Poly Medicure Ltd.

NSE: POLYMED · Healthcare

₹1,612.30+0.63%06 Nov 2026

Ask the data

Instant answers about Poly Medicure Ltd. — computed from its filings, no language model

Market cap₹16,342 cr

Current price₹1,612.30

High / Low₹2,063 / ₹1,191

P/E51.3

P/B5.00

Book value₹322.1

ROE9.8%

ROCE12.2%

Debt / equity0.12

Dividend yield0.22%

EPS (TTM)₹31.41

Face value₹5

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 7 periods

	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	687	786	923	1,115	1,376	1,670	1,875
EBITDA	164	214	213	265	358	453	442
Operating margin	23.9%	27.3%	23.1%	23.8%	26.0%	27.1%	23.6%
Interest	18	9	4	9	11	12	18
Depreciation	41	48	54	57	64	83	116
Profit before tax	124	177	193	236	342	447	422
Tax	30	44	49	58	86	114	107
Net profit	0	136	147	179	258	339	322
EPS ₹	10.86	15.25	15.28	18.69	26.92	34.13	31.79
Operating cash flow	—	—	123	191	266	241	241
Capex	—	—	156	239	277	325	308
Dividend paid	—	—	24	24	29	30	35
Total assets	—	1,224	1,377	1,577	1,859	3,192	3,919
Equity	—	966	1,087	1,242	1,470	2,766	3,106

Quarterly performance

last 29 quarters · ₹ crore

showing latest 8 of 29 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	162	174	180	171	170	200	204	213	212	223	230	258	275	285	307	321	337	340	378	385	420	424	441	403	444	494	535	525	581
Operating profit	36	42	46	40	46	57	58	54	55	51	51	56	65	71	83	87	84	90	97	104	115	115	119	106	115	111	110	125	138
Operating margin	22.5%	24.1%	25.2%	23.4%	26.9%	28.3%	28.4%	25.4%	26.1%	22.8%	22.2%	21.6%	23.5%	24.9%	27.1%	27.2%	25.0%	26.6%	25.5%	27.0%	27.5%	27.0%	27.1%	26.3%	25.8%	22.5%	20.7%	23.8%	23.7%
Other income	4	5	4	5	3	3	5	7	10	12	7	8	9	14	8	13	14	17	15	17	26	22	24	42	34	26	18	33	19
Interest	3	2	5	8	3	3	5	-2	3	0	-1	1	0	5	2	2	2	3	3	3	3	3	2	3	3	6	6	6	7
Depreciation	10	10	11	9	11	11	13	13	13	14	14	14	14	14	15	16	16	16	16	20	21	22	21	23	25	29	38	36	35
Profit before tax	27	35	33	28	36	46	46	50	50	49	45	49	59	66	75	83	80	87	92	98	117	112	121	122	121	96	84	116	124
Tax	8	7	9	6	10	11	11	13	13	12	11	13	16	17	16	20	19	23	24	24	31	28	31	30	30	27	20	32	30
Net profit	20	28	25	0	27	35	35	39	0	38	35	36	44	50	59	63	62	65	68	74	87	85	92	93	92	71	66	86	95
EPS ₹	2.24	3.22	2.83	2.57	3.03	3.97	4.00	4.26	3.92	3.99	3.60	3.77	4.53	5.21	6.13	6.54	6.48	6.78	7.12	7.71	9.01	8.48	8.92	9.19	9.06	7.00	6.54	8.49	9.38
Revenue YoY	—	—	—	—	5.4%	14.8%	12.8%	24.3%	24.4%	11.9%	13.2%	20.9%	23.0%	23.7%	19.2%	—	22.8%	19.2%	23.2%	19.9%	24.5%	24.9%	16.6%	4.8%	5.7%	16.4%	21.3%	30.3%	30.8%
Profit YoY	—	—	—	—	34.8%	23.3%	41.1%	—	-100.0%	9.2%	-2.3%	-6.9%	13.8%	44.9%	62.6%	—	43.0%	30.0%	16.2%	18.1%	40.6%	31.1%	34.3%	25.7%	5.0%	-16.8%	-27.8%	-7.6%	3.6%

Earlier results (standalone, Sep '07 – Mar '19)

₹ crore · from BSE, before the NSE XBRL filings begin

Poly Medicure Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†
Revenue	112	209	252	312	374	394	443	510	587
Operating profit	17	44	51	73	84	84	92	120	134
Operating margin	15.5%	21.1%	20.3%	23.3%	22.6%	21.4%	20.8%	23.5%	22.9%
Other income	1	1	0	5	6	8	11	14	16
Interest	5	6	6	8	8	8	7	10	13
Depreciation	6	10	12	14	18	20	23	28	36
Profit before tax	7	29	34	62	84	65	73	96	101
Tax	1	10	10	19	23	18	20	26	34
Net profit	6	19	24	43	61	47	53	70	66

Quarters

showing latest 8 of 45 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	JUN '10†	SEP '10†	DEC '10†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†
Revenue	22	21	23	23	30	28	31	31	31	34	38	44	42	46	50	55	57	58	62	63	69	71	80	80	82	83	96	97	98	95	100	92	107	103	107	116	118	109	135	126	140	131	147	149	160
Operating profit	2	2	3	4	5	4	4	5	6	8	8	9	9	11	11	10	12	9	9	16	17	18	21	17	16	19	24	22	19	18	21	20	26	23	23	26	20	23	34	30	33	31	35	33	36
Operating margin	11.2%	11.7%	13.6%	17.2%	17.4%	13.0%	14.5%	17.5%	20.7%	23.3%	21.6%	19.8%	20.7%	24.1%	21.1%	18.1%	21.4%	15.4%	14.2%	26.1%	24.6%	26.0%	26.3%	21.0%	20.1%	23.3%	24.7%	22.7%	19.7%	18.9%	20.6%	21.3%	24.5%	22.5%	21.5%	22.5%	17.0%	21.3%	25.3%	23.5%	23.5%	23.8%	23.5%	22.1%	22.2%
Other income	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1	0	1	4	1	2	3	2	2	2	2	3	4	4	3	4	5	3	4	4	5
Interest	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	2	1	1	2	2	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	3	4	6	1	2
Depreciation	1	1	2	2	2	1	1	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	4	4	4	5	5	5	5	5	5	5	6	6	6	7	7	7	8	9	9	9	9
Profit before tax	2	2	2	1	2	1	2	3	4	5	5	6	5	8	7	6	8	4	5	12	13	14	16	15	17	14	38	19	14	13	17	14	21	18	18	21	16	18	27	24	27	22	23	26	29
Tax	-0	0	0	0	0	0	0	0	0	1	0	1	0	2	2	2	3	1	1	3	4	4	5	4	5	4	11	7	2	3	5	4	7	5	6	6	3	6	9	8	3	9	9	9	8
Net profit	3	2	1	1	2	1	2	2	4	4	5	5	5	5	5	4	5	3	3	8	9	10	11	11	11	10	27	12	12	10	13	11	14	13	12	15	13	12	19	17	23	14	14	17	21
EPS ₹	4.77	4.06	2.74	2.36	3.66	1.17	3.56	4.46	7.03	8.12	4.42	4.41	4.39	4.84	4.33	3.64	4.68	2.77	3.16	7.49	8.40	8.67	5.01	5.01	5.17	4.41	12.38	5.38	2.74	2.21	2.86	2.39	3.27	2.87	2.82	3.41	1.50	1.36	2.11	1.89	2.62	1.54	1.64	1.91	2.43
Revenue YoY	—	—	—	—	39.2%	29.7%	32.2%	32.8%	3.5%	22.4%	23.1%	39.1%	22.9%	20.3%	15.8%	32.2%	—	25.3%	23.5%	14.2%	20.9%	22.3%	27.6%	27.5%	18.4%	17.2%	20.2%	21.3%	19.6%	15.1%	5.0%	-5.6%	9.1%	7.8%	6.1%	26.1%	10.6%	5.8%	26.5%	8.5%	18.9%	20.9%	8.8%	18.3%	13.9%
Profit YoY	—	—	—	—	-21.7%	-70.7%	33.3%	89.2%	91.6%	587.7%	98.0%	25.6%	8.1%	9.4%	-1.9%	-17.0%	—	-42.8%	-27.0%	105.7%	79.6%	213.1%	217.2%	34.1%	23.0%	1.7%	147.0%	7.9%	6.3%	0.4%	-53.8%	-11.7%	19.1%	29.8%	-1.4%	42.7%	-7.9%	-5.1%	49.6%	10.0%	73.8%	13.3%	-22.2%	1.8%	-6.9%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 23 periods

	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	21.6%	23.7%	25.6%	28.7%	14.1%	11.3%	11.6%	11.6%	10.0%	17.3%	17.5%	18.6%	17.6%	18.3%	11.4%	12.2%	12.2%	12.9%	12.4%	11.9%	10.4%	10.1%	9.8%
ROCE	31.6%	33.3%	35.9%	38.4%	16.8%	18.2%	18.3%	17.8%	16.2%	21.1%	21.5%	22.8%	21.6%	22.5%	14.8%	15.7%	15.6%	16.4%	15.4%	15.0%	12.8%	12.7%	12.2%
Net margin	10.7%	11.5%	12.0%	13.0%	17.3%	13.2%	13.2%	12.7%	11.8%	18.1%	18.7%	19.1%	18.8%	18.7%	19.4%	19.6%	20.3%	21.2%	21.1%	19.5%	17.2%	15.8%	14.9%
EBITDA margin	23.9%	24.9%	26.1%	26.9%	27.3%	27.0%	25.6%	24.1%	23.1%	25.8%	26.1%	26.4%	26.0%	26.0%	26.7%	26.8%	27.1%	27.0%	26.6%	25.3%	23.6%	23.1%	22.7%
Debt / equity	0.33	0.33	0.33	0.33	0.14	0.14	0.14	0.14	0.12	0.12	0.10	0.10	0.12	0.12	0.06	0.06	0.06	0.06	0.08	0.08	0.11	0.11	0.12
Interest coverage	7.75	8.38	8.47	9.38	21.77	22.41	31.70	199.39	46.26	28.94	26.58	31.85	31.31	30.86	31.14	33.35	38.28	40.94	42.54	33.66	24.06	20.04	17.11
Asset turnover	1.22	1.23	1.28	1.32	0.64	0.68	0.70	0.72	0.67	0.75	0.74	0.77	0.74	0.77	0.50	0.53	0.52	0.53	0.48	0.50	0.48	0.51	0.51

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 16 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	22	22	22	44	44	48	48	48	48	48	48	51	51	51	51	51
Other equity / reserves	124	196	229	227	294	918	1,040	1,086	1,194	1,290	1,422	2,541	2,715	2,868	3,055	3,215
Total equity	146	218	251	272	338	966	1,087	1,134	1,242	1,338	1,470	2,591	2,766	2,918	3,106	3,265
Borrowings	49	61	65	80	111	134	125	128	146	133	170	158	178	236	342	386
Current liabilities	—	—	—	114	123	171	227	265	293	321	351	417	370	501	576	649
Non-current liabilities	—	—	—	72	104	87	63	49	42	38	37	44	57	154	194	198
Total assets	286	364	387	457	565	1,224	1,377	1,448	1,577	1,697	1,859	3,052	3,192	3,587	3,919	4,155
Property, plant & equipment	120	161	176	194	249	374	439	450	587	647	819	914	1,038	1,152	1,255	1,350
Capital work-in-progress	13	4	—	12	10	15	37	89	73	96	67	62	90	83	91	110
Investments	3	4	4	3	15	354	346	258	126	165	167	1,090	1,077	930	755	746
Inventories	42	58	46	62	73	126	168	196	209	213	221	270	286	347	434	512
Receivables	46	63	83	96	113	156	207	216	235	252	270	328	350	426	531	559
Cash & equivalents	14	20	22	1	4	5	8	13	7	12	12	13	9	26	51	58

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 11 periods

	FY14‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	66	56	75	106	128	119	123	191	266	241	241
Cash from investing	-58	-56	-88	-101	-107	-436	-85	-179	-241	-1,191	-225
Cash from financing	5	-0	16	-5	-21	317	-35	-13	-20	953	20
Capex	59	59	82	78	106	95	156	239	277	325	308
Free cash flow	8	-3	-8	28	22	24	-32	-48	-11	-84	-68
Dividends paid	—	—	—	—	—	—	24	24	29	30	35

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹1,350 cr32%

CWIP

₹110 cr3%

Investments

₹746 cr18%

Inventories

₹512 cr12%

Receivables

₹559 cr13%

Cash & equivalents

₹58 cr1%

Other assets

₹820 cr20%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Poly Medicure Ltd.	16,342	1,612.30	51.3	5.00	9.8%

StoxGud checklist: Neutral setup · 6/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-0.2%

6 months-4.0%

1 year-18.1%

3Y CAGR+5.5%

5Y CAGR+12.2%

10Y CAGR+23.6%

50-day avg₹1,633.01

200-day avg₹1,545.37

RSI (14)52

Compare Poly Medicure Ltd. with

Onesource Specialty Pharma vs Poly Medicure Caplin Point Laboratories vs Poly Medicure Syngene International vs Poly Medicure Cohance Lifesciences vs Poly Medicure Poly Medicure vs Vijaya Diagnostic Centre Poly Medicure vs NATCO Pharma Poly Medicure vs Rainbow Childrens Medicare Poly Medicure vs Concord Biotech

FAQs

What is the share price of Poly Medicure Ltd.?

Poly Medicure Ltd. (POLYMED) closed at ₹1,612.30 on NSE on 06 Nov 2026.

What is the market cap of Poly Medicure Ltd.?

₹16,342 crore at the latest close.

What is the P/E ratio of Poly Medicure Ltd.?

51.3, on trailing-twelve-month earnings from its filings.

How fast is Poly Medicure Ltd. growing?

Poly Medicure Ltd.: revenue has compounded at 18.9% a year over three years; net profit at 21.6% a year. Latest-quarter revenue is up 30.8% year on year, profit up 3.6%.

How profitable is Poly Medicure Ltd.?

On a trailing-twelve-month basis return on equity is 9.8%, return on capital employed 12.2%, operating margin 22.7%, net margin 14.9%.

How much debt does Poly Medicure Ltd. have?

Poly Medicure Ltd. is lightly geared: debt to equity is 0.12 with borrowings of ₹386 cr against cash of ₹58 cr (balance sheet of 2026-09-30). Operating profit covers interest 17.1 times.

Financials parsed from Poly Medicure Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '19, annual from FY20, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.